Med Ad News’ Post

This Week in Drug Pricing: Patient advocate introduces POTUS, P4AD launches new tool to defend Medicare negotiations, and how the Inflation Reduction Act is lowering drug costs for women. Learn more in our Week In Review: https://lnkd.in/eq8cUece

Did you know stigma and discrimination can lead to avoidance of care? Learn the top 10 actionable strategies to improve #pharmacy care for 2SLGBTQIA+ patients. 🎥 Watch the video & download the accompanying quick reference tool: https://ow.ly/LOgW50PO1PQ

The 1/15 Healthcare Labyrinth Newsfeed is live! Click below to read! Today's topics include: -- Trends identified from the JPM healthcare conference. -- AI can help identify SDOH barriers. -- Drug importation faces barriers. -- Asthma inhaler price and patent investigation. -- KFF healthcare costs review. -- The wealthy Sackler Family can do more for their role in the opioid crisis. #healthcare #healthinsurance #healthcarereform #healthcarelabyrinth

The latest from 340B Report: Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition - https://lnkd.in/eYFqqdhp AHA Urges Dropping Bill Language to Exclude Generic Injectables from 340B - https://lnkd.in/ejPFe_B7 5 Best Practices for Running and Optimizing a Mixed-Use Program - https://lnkd.in/eFpTCZhf Provider-PhRMA Coalition Adds Civil Rights Group - https://lnkd.in/eNizte3h From the Publisher & CEO: The Big Question on the Minds of Every 340B Stakeholder - https://lnkd.in/eJ7RcSKY #340B #pharmacy #hospitals #drugspharmaceuticals #drugpricing

Beware these 5 “value-killers” when assessing the clinical benefits of a drug: 1. Lack of clinically meaningful improvement in survival 2. Lack of clinically meaningful improvement in quality of life 3. Serious adverse effects 4. Effectiveness < Efficacy 5. Potential for non-adherence #employeebenefits #valuebasedcare #evidencebasedmedicine

While cost-sharing can be expressed as a well-intended benefit design, it can negatively affect long-term drug adherence by patients. AMCP supports efforts to reduce out-of-pocket costs where appropriate, including provisions of the Inflation Reduction Act. However, there could be long-term and unintended consequences in reducing premiums, so it is crucial to develop comprehensive and patient-centric solutions to address these issues over time. AMCP, along with our partners, look forward to our continued efforts to address these complex solutions. https://bit.ly/3T6LSFH #drugpricing #healthequity #patientaccess

TCET Timing, EU Reforms, Opioid Devices, and More In this week's Pathways Picks: • CMS signals its final Transitional Coverage for Emerging Technologies pathway could be published this month • EU makes official several #IVDR and #MDR reforms • CMS issues its outpatient payment proposed rule, where a device qualifies for a new opioid-alternative payment • FDA addresses opioid disorder treatment devices and misinformation in #guidance docs • More news from Europe, Japan, and China Get your picks here: https://bit.ly/3Lo84aM #medtech

Drug #shortages are a significant problem that will and have put patient care in jeopardy. We need to solve this issue NOW. There are policy solutions that the federal government can deploy. Listen to the latest episode of Healthcare Matters Conner Mertens Global Healthy Living Foundation Progressive Policy Institute Pioneer Institute for Public Policy Research https://lnkd.in/esncqV4D

Asking patients about their overdose history is an important step healthcare providers can take in preventing overdose. Unsure how to ask? Call 855-337-MACS for free expert consultation on talking to patients about drug use, screening tools, and more. #IOAD2023 #OverdoseAwareness

The FDA's fast track approval programs for serious conditions have been criticized, leading to a loss of sponsors. Why not extend these programs to the millions of Americans living with chronic pain? By streamlining the approval process for new treatments, we can help those suffering from chronic pain access the care they need faster. It's time to prioritize the needs of those living with chronic pain and explore new ways to support them. Learn more about the FDA's approval programs at the link below. #FDA #chronicpain #healthcare #patientcare